-
公开(公告)号：EP2562183A1
公开(公告)日：2013-02-27
申请号：EP12191623.3
申请日：2008-07-25
发明人： Singh, Harpreet , Schoor, Oliver , Trautwein, Claudia , Hilf, Norbert , Weinschenk, Toni , Waltere, Steffen , Lewandrowski, Peter
CPC分类号： A61K39/0011 , A61K35/17 , A61K2039/5158 , A61K2039/572 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/495 , C07K14/7051 , C07K16/40 , C07K19/00 , C07K2317/34 , C07K2319/00 , C12N5/0638 , C12N9/0036 , C12N9/13 , C12N2502/1157 , C12Y208/02011
摘要： The present invention relates to amino acid sequences of peptides derived from tumour associated antigens that are able to bind to MHC complexes of either class, and elicit an immune response, as well as to uses of said peptides for the treatment of diseases.
-
252.发明公开NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER 有权新型免疫疗法针对不同肿瘤，包括胃肠道和胃癌
公开(公告)号：EP2547354A2
公开(公告)日：2013-01-23
申请号：EP11711292.0
申请日：2011-03-15
IPC分类号： A61K38/17
CPC分类号： A61K38/1709 , A61K39/0011 , A61K2039/5158 , A61K2039/572 , A61K2039/585 , A61P35/00 , C07K7/06 , C07K2319/00 , G01N33/505
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
253.发明公开NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS 有权的肿瘤相关肽及相关的抗癌疫苗治疗胶质母细胞瘤（GBM）和其它癌症组成
公开(公告)号：EP2341927A2
公开(公告)日：2011-07-13
申请号：EP09778750.1
申请日：2009-09-28
发明人： SCHOOR, Oliver , HILF, Norbert , WEINSCHENK, Toni , TRAUTWEIN, Claudia , WALTER, Steffen , SINGH, Harpreet
CPC分类号： A61K39/0011 , A61K35/17 , A61K38/00 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55561 , A61K2039/55588 , A61K2039/572 , A61K2039/605 , A61K2039/6081 , A61K2039/6093 , A61M5/002 , C07K7/06 , C07K7/08 , C07K14/70539 , C07K2319/00 , C07K2319/40 , C12N5/0638 , C12N2501/50 , G01N33/57492 , Y02A50/472
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 25 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
摘要翻译： 本发明涉及肽，核酸和细胞免疫治疗方法中使用。 特别地，本发明涉及癌症的免疫疗法。 本发明进一步更涉及肿瘤相关细胞毒性T细胞（CTL）肽表位，单独或与其它肿瘤相关肽组合并用作疫苗组合物的活性药物成分并刺激抗肿瘤免疫应答。 本发明涉及由HLA衍生25个的新的肽序列的变体及其I类和人肿瘤细胞的II型分子并能在疫苗组合物可用于引发抗肿瘤免疫应答。
-
254.发明授权IMMUNOGENIC T-HELPER EPITOPES FROM HUMAN TUMOUR ANTIGENS AND IMMUNOTHERAPEUTIC METHODS USING SAID EPITOPES 有权人类肿瘤抗原的免疫原性T辅助表位和它们在免疫治疗方法
公开(公告)号：EP1794190B9
公开(公告)日：2010-05-19
申请号：EP05778354.0
申请日：2005-09-09
IPC分类号： C07K14/47 , G01N33/574 , C12N15/62
CPC分类号： C07K14/4748
-
公开(公告)号：EP2014673B1
公开(公告)日：2010-05-05
申请号：EP08014305.0
申请日：2003-03-27
CPC分类号： C07K7/06 , A61K38/00 , A61K48/00 , A61K2039/5158 , C07K14/4748 , G01N33/505 , G01N33/56977 , G01N33/574 , Y10S530/828
-
256.发明公开Novel immunotherapy against several tumors including neuronal and brain tumors 有权针对几种肿瘤包括神经元和脑肿瘤的新型免疫疗法
公开(公告)号：EP2172212A3
公开(公告)日：2010-04-14
申请号：EP08017921.1
申请日：2008-10-13
发明人： Schoor, Oliver , Hilf, Norbert , Weinschenk, Toni , Trautwein, Claudia , Walter, Steffen , Singh, Harpreet
CPC分类号： A61K39/0011 , A61K35/17 , A61K38/00 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55561 , A61K2039/55588 , A61K2039/572 , A61K2039/605 , A61K2039/6081 , A61K2039/6093 , A61M5/002 , C07K7/06 , C07K7/08 , C07K14/70539 , C07K2319/00 , C07K2319/40 , C12N5/0638 , C12N2501/50 , G01N33/57492 , Y02A50/472
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 25 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
摘要翻译： 本发明涉及用于免疫治疗方法的肽，核酸和细胞。 具体而言，本发明涉及癌症的免疫治疗。 本发明还涉及单独或与其他肿瘤相关肽组合的肿瘤相关的细胞毒性T细胞（CTL）肽表位，所述肽用作刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分。 本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的25种新的肽序列及其衍生自人类肿瘤细胞的HLA I类和II类分子的变体。
-
257.发明授权Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines 有权肿瘤相关肽的新型制剂结合于免疫接种I或II类的人白细胞抗原
公开(公告)号：EP2113253B1
公开(公告)日：2010-03-31
申请号：EP08008292.8
申请日：2008-04-30
CPC分类号： A61K39/0011 , A61K9/0019 , A61K9/19 , A61K38/08 , A61K38/10 , A61K47/10 , A61K47/26 , A61K2039/55555 , Y10T428/13
-
258.发明公开Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines 有权肿瘤相关肽的新型制剂结合于免疫接种I或II类的人白细胞抗原
公开(公告)号：EP2113253A1
公开(公告)日：2009-11-04
申请号：EP08008292.8
申请日：2008-04-30
CPC分类号： A61K39/0011 , A61K9/0019 , A61K9/19 , A61K38/08 , A61K38/10 , A61K47/10 , A61K47/26 , A61K2039/55555 , Y10T428/13
摘要： The present invention relates to novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules as vaccines for the use in immunotherapeutic methods. In particular, the present invention relates to formulations for the immunotherapy of cancer, in particular renal cancer. The present invention furthermore relates to vaccine compositions for eliciting anti-tumour immune responses.
摘要翻译： 本发明涉及肿瘤相关肽结合人白细胞抗原（HLA）I类或II类分子作为疫苗用于免疫治疗方法中的用途的新颖的式灰。 特别地，本发明涉及式灰用于癌症免疫疗法，尤其是肾癌。 本发明进一步更涉及疫苗组合物用于引发抗肿瘤免疫应答。
-
公开(公告)号：EP2105501A1
公开(公告)日：2009-09-30
申请号：EP08005889.4
申请日：2008-03-27
发明人： Emmerich, Niels , Singh, Harpreet , Schoor Oliver
CPC分类号： C07K14/4748
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 10 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
260.发明授权Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine 有权肿瘤相关肽的HLA I类或II类分子结合，以及抗肿瘤疫苗
-
-
-
-
-
-
-
-
-
搜索结果
268 条记录 (耗时 0.041 秒)
